Advertisement
Disease Research
Subscribe to Disease Research

The Lead

Potential Flu Drugs Target Immune Response, Not Virus

July 22, 2014 2:07 pm | News | Comments

The seriousness of disease often results from the strength of immune response, rather than with the virus, itself. Turning down that response, rather than attacking the virus, might be a better way to reduce that severity. Read more...         

HIV Pills Show More Promise to Prevent Infection

July 22, 2014 1:47 pm | News | Comments

There is more good news about HIV treatment pills used to prevent infection in people at high...

Easing Drug-Induced Fatty Liver Disease in HIV Patients

July 22, 2014 1:40 pm | News | Comments

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop...

PSI, AOP Orphan Collaborate on Global Rare Disease Trial

July 22, 2014 11:56 am | News | Comments

PSI CRO, a full-service contract research organization, announced the launch of a new global...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Ganymed Completes Recruitment for Gastroesophageal Cancer Drug Trial

July 22, 2014 11:33 am | News | Comments

Ganymed Pharmaceuticals AG, a biopharmaceutical company developing Ideal Monoclonal Antibodies for the treatment of cancer, announced that it has completed recruitment of 210 patients for its Phase 2 FAST clinical trial to evaluate the combination of IMAB362 and chemotherapy as first-line therapy in patients with gastroesophageal cancer. Read more...

FDA Grants Avastin Priority Review for Ovarian Cancer

July 22, 2014 11:05 am | News | Comments

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. Read more...

MedImmune, Advaxis Partner on Immuno-Oncology Combo Trial

July 22, 2014 10:59 am | News | Comments

AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis Inc., a US-based biotechnology company developing cancer immunotherapies, providing further evidence of MedImmune’s commitment to explore novel combination approaches. Read more...

Advertisement

Metabolic Enzyme Stops Renal Cancer Progression

July 22, 2014 10:52 am | News | Comments

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. Read more...

Genetic Mapping Triggers Hope for Schizophrenia

July 22, 2014 10:40 am | by Seth Borenstein, AP Science Writer | News | Comments

Scientists have linked more than 100 spots in our DNA to the risk of developing schizophrenia, casting light on the mystery of what makes the disease tick, providing the first hard genetic evidence to bolster a theory connecting the immune system to the disease. Read more...

NIH Grants Sorrento Funding for Development of Small Molecule Inhibitor

July 21, 2014 3:57 pm | News | Comments

Sorrento Therapeutics Inc. announced that it has received non-dilutive funding for the preclinical development of a small molecule inhibitor targeting the important oncogenic transcription factor Myc. Read more…           

Dipexium Launches Phase 3 Trial of Foot Ulcer Antibiotic

July 21, 2014 3:37 pm | News | Comments

Dipexium Pharmaceuticals Inc. announced it has initiated patient enrollment in the second of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex for the treatment of patients with mild infections of diabetic foot ulcers. Read more...

Antipsychotic Drugs Linked to Decreased Brain Volume

July 21, 2014 3:18 pm | News | Comments

A new study has confirmed a link between antipsychotic medication and a slight, but measureable, decrease in brain volume in patients with schizophrenia. Read more...                        

Advertisement

Gold Nanoparticles Penetrate Cells, Show Promise for Drug Delivery

July 21, 2014 3:09 pm | Videos | Comments

A special class of tiny gold particles can easily slip through cell membranes, making them good candidates to deliver drugs directly to target cells. Read more...                          

MetaMax Enrolls First Patients in Trial of Anticancer Drug

July 21, 2014 11:58 am | News | Comments

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. Read more...

First Patients Enrolled in Trial of Opioid Dependence Treatment

July 21, 2014 11:49 am | News | Comments

Braeburn Pharmaceuticals announced that the first patients have been enrolled in its Phase 3 clinical study of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence, for which there is an acute need for innovative and effective treatment options. Read more...

Combo Therapy Cures Hep C in Co-Infected HIV Patients

July 21, 2014 11:37 am | News | Comments

A multicenter team of researchers report that in a Phase 3 clinical trial, a combination drug therapy — sofosbuvir and ribavirin — cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C. Read more...

China’s FDA Approves Conduct of Breast Cancer Trial

July 21, 2014 11:31 am | News | Comments

CASI Pharmaceuticals Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced that China's Food and Drug Administration has approved the company's application to conduct a Phase 2 clinical trial in triple-negative breast cancer patients in China for its proprietary drug candidate, ENMD-2076. Read more...

Advertisement

Researchers Aim to Help Doctors Attack Metastases

July 21, 2014 11:22 am | News | Comments

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient’s immune response against tumors. Read more...

JDRF, ViaCyte File IND App for Diabetes Treatment Trial

July 18, 2014 3:30 pm | News | Comments

JDRF announced that ViaCyte Inc. has filed an Investigational New Drug application (IND) with the FDA seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. Read more...                

Amgen's Hyperparathyroidism Drug Hits All Endpoints in Phase 3

July 18, 2014 3:16 pm | News | Comments

Amgen announced that a Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. Read more...   

Bayer Eye Drug Shows Sustained Vision Improvement in DME

July 18, 2014 3:08 pm | News | Comments

Bayer HealthCare announced that in the Phase 3 VIVID-DME trial of aflibercept solution for injection into the eye for the treatment of vision impairment due to diabetic macular edema (DME), the solution showed a sustained improvement from baseline in best corrected visual acuity (BCVA). Read more...

Researchers ID Possible Target for Early-Stage Breast Cancer Immunotherapy

July 18, 2014 2:59 pm | News | Comments

Researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. Read more...                         

Breakthrough May Benefit Bowel Cancer Treatments

July 18, 2014 2:50 pm | News | Comments

Researchers have made a significant breakthrough that may benefit patients with bowel cancer: how two genes cause bowel cancer cells to become resistant to treatments used against the disease. Read more...          

Prana Updates Alzheimer's Development Program

July 18, 2014 11:38 am | News | Comments

Prana Biotechnology updated its clinical development program for Alzheimer's disease, noting that the starting amyloid burden level (baseline) in the PBT2 treated participant group had an important bearing on the decrease of amyloid over time in that participant (p=0.035), whereas there was no such correlation in the placebo group.. Read more...

CDC Reports First Chikungunya Case Acquired in the U.S.

July 18, 2014 11:31 am | News | Comments

Seven months after the mosquito-borne virus chikungunya was recognized in the Western Hemisphere, the first locally acquired case of the disease has surfaced in the continental United States in Florida in a male who had not recently traveled outside the United States. Read more...

Researchers Create Biological Pacemakers with Gene Therapy

July 18, 2014 10:59 am | News | Comments

Cardiologists at the Cedars-Sinai Heart Institute have developed a minimally invasive gene transplant procedure that changes unspecialized heart cells into “biological pacemaker” cells that keep the heart steadily beating, potentially leading lead to clinical trials for humans with heart rhythm disorders but suffer side effects. Read more...

NEJM Publishes Ipsen Data Showing Prolonged PFS from Somatuline

July 17, 2014 2:44 pm | News | Comments

Ipsen announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline injection achieved statistically significant prolongation of progression free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Read more...

BMS, Pfizer Launch Phase 4 Eliquis Trial

July 17, 2014 1:54 pm | News | Comments

Bristol-Myers Squibb and Pfizer announced that the first patient has been enrolled into a Phase 4 clinical trial called EMANATE, assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Read more...

Arthritis Drug Shown to Slow Alzheimer’s

July 17, 2014 1:45 pm | News | Comments

A drug that is commonly used for arthritis has been shown to slow the progression of Alzheimer’s. A small randomized control study tested the drug Etanercept on patients with mild to moderate Alzheimer’s. Read more...          

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading